Customize GIP3 Antibody

Description

GIP Receptor (GIPR) Antibodies

GIPR antibodies are engineered to modulate the activity of the GIP receptor, a class B GPCR involved in insulin secretion and energy homeostasis.

Key Antibody Candidates

Antibody Name	Mechanism	Target Species	Key Findings
Gipg013	Competitive antagonist	Human, mouse	- Binds GIPR ECD, overlapping with GIP peptide binding site . - IC₅₀ = 7 nM (human GIPR) .
mAb2	Full antagonist	Mouse	- Reduces body weight gain in diet-induced obese mice (7-week study) . - IC₅₀ = 48 nM .
hGIPR-Ab	Bispecific conjugate	Human, monkey	- Conjugated to GLP-1 peptide for dual GIPR antagonism/GLP-1R agonism. - Synergistic weight loss in primates .

Preclinical Efficacy

Weight Loss: mAb2 reduced body weight gain by 15% in obese mice vs. controls .
Metabolic Effects: hGIPR-Ab/GLP-1 conjugates lowered respiratory exchange ratios in DIO mice, indicating increased fat oxidation .

Glypican-3 (GPC3) Antibodies

GPC3 antibodies target a proteoglycan overexpressed in hepatocellular carcinoma (HCC), enabling tumor-specific cytotoxicity.

Lead Clinical Candidates

Antibody Name	Format	Clinical Stage	Key Findings
hYP7	Humanized IgG1	Preclinical	- Induces ADCC/CDC in GPC3⁺ cells (EC₅₀ = 0.7 nM) . - Inhibits HCC xenograft growth in mice .
GC33	Humanized monoclonal	Phase I/II	- Median time to progression (TTP): 26.0 weeks (high GPC3) vs. 7.1 weeks (low GPC3) .
ab207080	Rabbit monoclonal	Research use	- Specific cytoplasmic/membrane staining in HepG2 cells (1/500 dilution) .

Mechanisms of Action

ADCC/CDC: hYP7 triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) at 0.12 μg/ml in GPC3⁺ cells .
Glycan Modulation: GPC3 antibodies alter heparan sulfate chains, inhibiting BMP4/FGF7 signaling pathways critical for HCC progression .

Clinical Progress

GC33: Demonstrated no dose-limiting toxicities in a Phase I trial (n=20) with dose-dependent TTP improvements .
Bispecifics: GPC3/CD47 bispecific antibodies outperform single-target therapies in mouse xenografts (p < 0.01) .

Comparative Analysis of Antibody Classes

Parameter	GIPR Antibodies	GPC3 Antibodies
Primary Indication	Obesity, diabetes	Hepatocellular carcinoma
Mechanism	Receptor antagonism/agonism	Tumor antigen targeting
Key Biomarker	GIP-induced cAMP reduction (IC₅₀ ≤50 nM)	GPC3 membrane expression (IHC score ≥2+)
Clinical Impact	Synergistic weight loss with GLP-1 drugs	Extended TTP in advanced HCC

Challenges and Future Directions

GIPR Antibodies: Optimizing pharmacokinetics to mitigate rapid clearance (e.g., IgG3 subclass engineering ).
GPC3 Antibodies: Overcoming heterogeneity in GPC3 expression across HCC subtypes .

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

GIP3 antibody; YPL137C antibody; GLC7-interacting protein 3 antibody

Target Names

GIP3

Uniprot No.

Q03016

Target Background

Gene References Into Functions

A study identified 245 genes essential for the normal growth of the Glc7 mutant. PMID: 18627629

Database Links

KEGG: sce:YPL137C

STRING: 4932.YPL137C

Protein Families

GIP3/HER1 family

Subcellular Location

Cytoplasm. Endoplasmic reticulum.

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

GIP3 Antibody